Switzerland grants conditional marketing authorisation for Novavax Covid-19 vaccine

Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland

Novavax announced that Swissmedic, the Swiss Agency for Therapeutic Products, has granted Novavax conditional marketing authorization (CMA) for Nuvaxovid Covid-19 vaccine (recombinant, adjuvanted) for active immunization to prevent Covid-19.

"We are proud that Switzerland is part of the growing list of countries to authorize Nuvaxovid and that people in Switzerland will have a protein-based Covid-19 vaccine option," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "As we continue to fight Covid-19, we think it is incredibly important that people have a choice in vaccine options. Nuvaxovid offers something different from the current portfolio of vaccines by using a more tried and tested technology platform, while still providing a strong efficacy and safety profile."

Novavax previously announced an agreement with the government of Switzerland for up to six million doses of Novavax' Covid-19 vaccine.